Bitcoin's recent weakness is attributed to a loss of confidence in its role as a store of value, with investors turning their attention to AI stocks instead. The expected recovery from a $58,000 bottom did not materialize, while AI stocks rebounded first, drawing dip buyers away from crypto. The crypto community's usual bullish support during declines has been quieter, and some early Bitcoin believers are hedging by buying other cryptocurrencies like ZEC or PRL. Additional concerns include stablecoin outflows and the potential removal of Strategy from MSCI, which continue to weigh on the broader crypto market despite some altcoins holding up better than Bitcoin.
Bitcoin's confidence issues are the subject, with Pluang market data providing context. Of 50 major cryptocurrencies priced on Pluang, 12 rose and 37 fell today. Bitcoin was priced at Rp1.264.899.010 with a 1-day change of -5.04%, Pluang order activity showed 27% Sell and 73% Buy, and the typical hold time was 113 days as of Nov 13, 2026 17:21 WIB.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
